Jul 2026· PLOS Digital Health· Vol 5, pp. e0001492· 0 citations· 95 references
Medicine
TL;DR
Automated meal detection and compensation algorithms show promise for integration into FAID systems, with encouraging detection performance and glycemic outcomes, but the evidence remains heterogeneous, and a substantial portion is still based on in-silico studies rather than clinical validation.
Abstract
Fully automated insulin delivery (FAID) systems aim to regulate blood glucose levels in individuals with type 1 diabetes with minimal user input. A key challenge to achieving full automation is the need for manual meal announcements. This review focuses on algorithms developed to detect and compensate for unannounced meals. A systematic literature search was conducted across PubMed, Scopus, IEEE Xplore, and Web of Science (2000 – 2025), and the review was reported in accordance with PRISMA guidelines. From 1205 initially retrieved articles, 69 studies met predefined eligibility criteria and were included in the final review. Extracted data included algorithm type, data source (in-silico or clinical), performance metrics, and glycemic outcomes where available. The reviewed algorithms include heuristic rule-based methods, machine learning models, and control systems theory approaches. While varying in complexity and detection strategies, these approaches aim to identify meal events and estimate carbohydrate intake for timely insulin dosing. Median performance across studies included a sensitivity of 88%, precision of 93%, and detection times ranging from 25 to 40 minutes. In-silico evaluations generally reported more false positives than in-vivo. Reported glycemic outcomes demonstrated time-in-range values between 65% and 89%, highlighting the potential of these systems to support fully autonomous glucose regulation. Automated meal detection and compensation algorithms show promise for integration into FAID systems, with encouraging detection performance and glycemic outcomes. However, the evidence remains heterogeneous, and a substantial portion is still based on in-silico studies rather than clinical validation. Challenges remain in minimizing false positives, ensuring generalizability across populations, and validating performance in real-word settings.
Close-loop insulin delivery systems seem to be a more clinically successful option for controlling diabetes mellitus than SAP therapy, and sensor-augmented and closed-loop systems offer better glucose control and lower hypoglycemia rates compared to traditional therapies.
Noor ul ain Saleem, Faraz Arshad, M. Qadri et al.· Annals of Medicine and Surge...· 0 citations
A practice-oriented evaluation of the indications, clinical benefits, and safety of modern diabetes technologies and suggests that technologies should be offered according to individual needs, abilities, preferences, and life circumstances and implemented early, including at the time of diagnosis.
A. Mathew, D. Führer· Die Innere Medizin· 0 citations
A computerized ISC-based insulin infusion protocol resulted in more blood glucose values in target range and lower rates of hypoglycemia compared with paper-based protocols.
Amy K Janowski, Nandini Patel, Lydia R. Ware et al.· Journal of Diabetes Science...· 0 citations
Glycemic outcomes with simplified bolusing were non-inferior to carbohydrate counting, suggesting carbohydrate counting ability should not affect AID access.
Georgia M. Davis, Gregory P. Forlenza, B. Gehr et al.· Diabetes Research and Clinic...· 0 citations
Randomized and real-world studies demonstrate that AID systems significantly improve A1C and time in range while minimizing hypoglycemia, without increasing treatment complexity or patient burden, and position AID as a practical and effective strategy to overcome long-standing therapeutic inertia in type 2 diabetes.
Z. Tariq, Grazia Aleppo, Anders L. Carlson et al.· Endocrine Practice· 0 citations
RL-based AID systems represent an important step towards fully autonomous and personalized artificial pancreas solutions and will be dependent on multidisciplinary collaboration between AI researchers, clinicians, and regulators to ensure safety, transparency, and reliability in next generation diabetes management.
Madhav Prasad, Neha Tyagi, K. K. Sarma· Genetics and Molecular Resea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.